Double-blind, Randomized, Placebo-controlled, Multi-center Trial to Determine the Safety and Antiviral Effect of 3 Days of BZF961 With or Without Ritonavir Boosting in Hepatitis C Virus (HCV) Infected Patients
Phase of Trial: Phase I/II
Latest Information Update: 02 Sep 2018
At a glance
- Drugs BZF 961 (Primary) ; Ritonavir
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Novartis
- 02 Sep 2018 Results (n=54) published in the Clinical Therapeutics.
- 11 Mar 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 26 Aug 2014 Planned End Date changed from 1 Jan 2015 to 1 Dec 2014 as reported by ClinicalTrials.gov record.